0LB2 Stock Chart & Stats
$47.68
$0.00(0.00%)
At close: 4:00 PM EDT
$47.68
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$36.07 - $59.74
Previous CloseN/A
Volume1.00
Average Volume (3M)15.00
Market Cap
$2.59B
Enterprise Value$2.37K
Total Cash (Recent Filing)$372.07M
Total Debt (Recent Filing)$29.43M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding58,039,722
10 Day Avg. Volume7
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.64
Price to Sales (P/S)3.90
P/FCF Ratio61.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$63.50Price Target Upside33.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.49
Revenue Forecast (FY)$867.33M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Product MomentumSustained high single- to mid-teens organic growth and a 39% YoY revenue increase signal durable commercial traction across core CNS franchises. Broad prescription gains (KELLI, GOCOVRI, partner XERJUVEY) suggest expanding market penetration and recurring demand that support longer-term revenue scalability and reinvestment.
Conservative Balance Sheet And Cash RunwayA substantial cash balance with no debt provides strategic flexibility to fund R&D, commercial expansion, working capital or M&A without near-term refinancing risk. This liquidity cushion helps absorb GAAP losses or FCF variability and supports execution of multi-quarter initiatives like supplier qualification or integration planning.
Very High Gross Margins And Positive Cash GenerationConsistently very high gross margins across product portfolio provide durable operating leverage as revenue scales. Positive operating and free cash flow historically, even amid GAAP losses, indicates strong cash conversion that can support reinvestment, cover milestone payments and improve long-term profitability as fixed costs are absorbed.
Bears Say
Unstable Profitability And Large TTM Net LossThe swing to a sizable trailing‑twelve‑month net loss and negative operating margin undermines return metrics and signals that ongoing operating expense growth may outpace near-term revenue gains. Persistent GAAP losses constrain retained earnings, depress ROE, and raise execution risk until scale or expense control restores consistent profitability.
Weakening Free Cash Flow MomentumA marked decline in free cash flow trajectory reduces the company’s financial cushion and limits optionality for R&D, commercial investment or milestone obligations. If the FCF trend persists, the firm may face tougher choices on funding priorities, potentially slowing pipeline programs or requiring financing that dilutes flexibility.
Supply Constraints And Dependence On Second SupplierOngoing processing friction, high enrollment-to-shipment drop‑offs and a backlog indicate structural commercialization and manufacturing fragility. Reliance on a second supplier pending regulatory approval creates durable timing and execution risk that can materially delay revenue conversion and patient retention even as demand exists.
Supernus Pharmaceuticals News
0LB2 FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest share price was $36.07 and its highest was $59.74 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.59B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 98 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported $0.526 earnings per share for the quarter, beating the consensus estimate of $0.422 by $0.104.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Supernus Pharmaceuticals dividends here
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.68.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 58,039,722 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.526 in its last earnings report, beating expectations of $0.422. Following the earnings report the stock price went up 6.132%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0LB2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.50 (33.18% Upside)
$63.50 (33.18% Upside)
Blogger Sentiment
Bullish
GB:0LB2 Sentiment 75%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
0LB2 Company Deck
0LB2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple products with robust revenue growth (total revenue +39% YoY; growth products +56% YoY), improving non-GAAP profitability, a healthy cash position (~$384M) and an advancing R&D pipeline. Offsetting these positives are meaningful increases in operating expenses (combined R&D and SG&A up ~40.8% YoY), ongoing GAAP losses (albeit reduced), supply constraints and conversion challenges for Onepco, and timing / regulatory risk related to bringing a second supplier online. Management reiterated full-year guidance ranges and emphasized continued focus on corporate development and supply backups. Overall, the positive top-line growth, improved profitability metrics, strong product-specific trends and solid balance sheet outweigh the near-term expense and supply risks.View all GB:0LB2 earnings summaries0LB2 Stock 12 Month Forecast
Average Price Target
$63.50
▲(33.18% Upside)